{
    "id": "34eec0b8-ef99-4d69-bd3f-da1373da2e49",
    "indications": {
        "text": "rapaflo\u00ae , selective alpha-1 adrenergic receptor antagonist , indicated treatment signs symptoms benign prostatic hyperplasia ( bph ) [ ( 14 ) ] . rapaflo indicated treatment hypertension .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "8 mg capsules taken orally daily meal . ( 2.1 ) 4 mg capsules taken orally daily meal moderate renal impairment [ creatinine clearance ( ccr ) 30-50 ml/min ] . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "white , opaque , hard gelatin 8 mg capsules . cap imprinted \u201c watson 152 \u201d green . body imprinted \u201c 8 mg \u201d green . 8 mg capsules supplied unit hdpe bottles : 30 capsules ( ndc 0023-6142-30 ) 90 capsules ( ndc 0023-6142-90 ) bottles 30 90 capsules supplied child-resistant closures . white , opaque , hard gelatin 4 mg capsules . cap imprinted \u201c watson 151 \u201d gold . body imprinted \u201c 4 mg \u201d gold . 4 mg capsules supplied unit hdpe bottles : 30 capsules ( ndc 0023-6147-30 ) bottles 30 capsules supplied child-resistant closures . storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15-30\u00b0c ( 59-86\u00b0f ) . [ usp controlled room temperature . ] protect light moisture . keep reach children .",
    "adverseReactions": "severe renal impairment ( ccr < 30 ml/min ) severe hepatic impairment ( child-pugh score > 10 ) concomitant strong cytochrome p450 3a4 ( cyp3a4 ) inhibitors ( e.g . , ketoconazole , clarithromycin , itraconazole , ritonavir ) [ ( 7.1 ) ] patients history hypersensitivity silodosin ingredients rapaflo [ ( 6.2 ) description ( 11 ) ]",
    "ingredients": [
        {
            "name": "SILODOSIN",
            "code": "CUZ39LUY82",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135929"
        }
    ],
    "organization": "Allergan, Inc.",
    "name": "RAPAFLO",
    "effectiveTime": "20201201",
    "indications_original": "RAPAFLO\u00ae, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [\n                     see\u00a0CLINICAL STUDIES (\n                     \n                        14\n                     \n                     )\n                     ]\n                     . RAPAFLO is not indicated for the treatment of hypertension.",
    "contraindications_original": "8 mg capsules taken orally once daily with a meal. ( 2.1 ) 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment [Creatinine Clearance (CCr) 30-50 mL/min]. ( 2.2 )",
    "warningsAndPrecautions_original": "White, opaque, hard gelatin 8 mg capsules\n                     . Cap is imprinted with \u201cWATSON 152\u201d in green. Body is imprinted with \u201c8 mg\u201d in green. 8 mg capsules are supplied in unit of use HDPE bottles of:\n                  \n                     30 capsules (NDC\n                         0023-6142-30)\n                     \n                     90 capsules (NDC\n                         0023-6142-90)\n                  \n                  Bottles of 30 and 90 capsules are supplied with child-resistant closures.\n                  \n                     White, opaque, hard gelatin 4 mg capsules\n                     . Cap is imprinted with \u201cWATSON 151\u201d in gold. Body is imprinted with \u201c4 mg\u201d in gold. 4 mg capsules are supplied in unit of use HDPE bottles of:\n                  \n                     30 capsules (NDC\n                         0023-6147-30)\n                  \n                  Bottles of 30 capsules are supplied with child-resistant closures.\n                  \n                     Storage\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F). [See USP controlled room temperature.] Protect from light and moisture.\n                  \n                     Keep out of reach of children.",
    "adverseReactions_original": "Severe renal impairment (CCr < 30 mL/min)\n                     \n                     Severe hepatic impairment (Child-Pugh score > 10)\n                     \n                     Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [\n                        see\u00a0DRUG INTERACTIONS (\n                        \n                           7.1\n                        \n                        )\n                        ]\n                        \n                     \n                     Patients with a history of hypersensitivity to silodosin or any of the ingredients of RAPAFLO [\n                        see ADVERSE REACTIONS (\n                        \n                           6.2\n                        \n                        )\u00a0and\u00a0DESCRIPTION (\n                        \n                           11\n                        )]",
    "drug": [
        {
            "name": "RAPAFLO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135929"
        }
    ]
}